<DOC>
	<DOCNO>NCT00387504</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fenretinide , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase I trial study side effect best dose fenretinide treat patient metastatic unresectable malignant solid tumor .</brief_summary>
	<brief_title>Fenretinide Treating Patients With Metastatic Unresectable Malignant Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose fenretinide patient metastatic unresectable malignant solid tumor . - Determine toxic effect drug patient . - Determine pharmacokinetics vivo activity drug patient . - Determine , preliminarily , disease tumor response patient treated drug . OUTLINE : This dose-escalation , multicenter study . Patients receive fenretinide IV continuously day 1-5 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Patients achieve complete partial response may continue receive fenretinide discretion study chair . Cohorts 3-6 patient receive escalate dos fenretinide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . Patients undergo blood sample collection determine plasma concentration ( pharmacokinetics ) fenretinide periodically course 1 end course 2-6 . After completion study treatment , patient follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 21 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor malignancy Metastatic and/or unresectable disease No standard curative palliative measure exist remain effective Measurable evaluable disease No known brain metastasis unless previously resect irradiated treatment steroid 1 month PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 02 Karnofsky PS 60100 % Life expectancy &gt; 3 month WBC ≥ 3,000/mm³ Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 75,000/mm³ Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN ( 5 time ULN patient know liver metastasis ) Creatinine normal OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior , , ≥ 6 month completion study treatment No uncontrolled diabetes mellitus high risk hypertriglyceridemia ( i.e. , fast serum glucose concentration &gt; 200 mg/dL OR hemoglobin A1C &gt; 7.5 % ) No egg allergy No history allergic reaction compound similar chemical biologic composition fenretinide ( e.g. , isotretinoin , vitamin A , tretinoin ) No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude compliance study requirement No know hypertriglyceridemia require medication No identify familial hyperlipidemia disorder PRIOR CONCURRENT THERAPY : Recovered prior therapy Prior treatment oral fenretinide allow provide severe toxicity occur At least 2 week since prior major surgery More 4 week since prior chemotherapy radiotherapy At least 6 week since prior nitrosoureas mitomycin C No concurrent investigational agent No concurrent anticancer chemotherapy No concurrent antioxidants* No concurrent hormoneablative agent , include steroid , except adrenal replacement antiinflammatory indication No concurrent anticancer agent therapies No concurrent herbal alternative therapies* No concurrent vitamin supplement ( e.g. , vitamin A , ascorbic acid , vitamin E ) * Standarddose multivitamin allow No concurrent medication may act modulators intracellular ceramide level ceramide cytotoxicity , sphingolipid transport , pglycoprotein , multidrug resistance protein 1 ( MRP1 ) , MRP1 drug/lipid transporter , include following* : Cyclosporine analogues Verapamil Tamoxifen analogue Ketoconazole Chlorpromazine Mifepristone Indomethacin Sulfinpyrazone NOTE : *Patients discontinue drug ≥ 1 week eligible No concurrent medication may cause pseudotumor cerebri , include follow : Tetracycline Nalidixic acid Nitrofurantoin Phenytoin Sulfonamides Lithium Amiodarone No concurrent total parenteral nutrition ( TPN ) intralipids No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>